Journal of Clinical Oncology 2025

85 papers
The 2025 edition of the Journal of Clinical Oncology features 85 papers focused on combination therapies, precision diagnostics, and the integration of artificial intelligence in clinical practice. Research themes include the evaluation of immunotherapy agents such as camrelizumab and durvalumab, often combined with chemotherapy or anti-angiogenic treatments for non-small cell lung cancer and biliary tract carcinomas. Clinical trials also investigate novel bifunctional agents like retlirafusp alfa for head and neck squamous cell carcinoma and the monotherapy ABP1019A for advanced solid tumors. Prolific contributors for the year include Jorge J. Nieva, Jennifer S. Temel, and Joel W. Neal. A notable trend in this year's research is the application of computational models to oncology. Studies explore the use of multimodal machine learning to predict treatment responses in pancreatic cancer and the implementation of large language models to identify lung cancer screening eligibility. Furthermore, generative AI is utilized to facilitate querying within large oncology databases. These developments reflect an emphasis on data-driven decision-making and the refinement of biomarker analysis, such as HER2 status and plasma ctDNA concordance in gastrointestinal malignancies.

Top Research Directions

Research directions most represented by Journal of Clinical Oncology 2025 papers.

Standardized Frameworks for Tumor Response Assessment 1
The Non-Additive Toxicity of Multi-Modal Adjunctive Therapies 1
Identifying Rare Driver Mutations in Cancer Genomes 1
Open-Label Bias in Clinical Trials 1
Generalizability Challenges in Small Cohort Clinical Studies 1

Top Authors

AuthorPapers
Jorge J. Nieva3
Jiang Bian2
Alexander Baras1
Amanda S Barnard1
Andreas Kleppe1
Baris Turkbey1
Benjamin Haibe-Kains1
Bradford J Wood1
Jakob Nikolas Kather1
Jeremy Yuen-Chun Teoh1
Jingchuan Guo1
Jinxi Xiang1
Jitesh Joshi1
Julian C. Hong1
Kui Jiang1
Rahul G Krishnan1
Yuming Jiang1
Zhijie Liu1
Zongliang Ji1

Papers

Title
Missed opportunity: PROMs as primary endpoints in bladder cancer trials.
MRI imaging and machine learning based radiomics for detection of mixed HCC and CCA tumors: Still a need for liver biopsy?
Multimodal machine learning predictions of treatment response and survival in advanced pancreatic cancer from the COMPASS trial.
Mutation rate differences across populations and association with performance disparities in pathology AI diagnostic models.
NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4 in participants with advanced or metastatic urothelial carcinoma or other solid tumors.
Oncoshare-Lung: Novel three-way linkage of neighboring academic and community medical centers to state cancer registry for lung cancer.
Open pilot of a culturally responsive, cognitive-behavioral intervention (PROWESS) for Black and Latino men receiving androgen deprivation therapy for prostate cancer.
Outcomes of high-risk prostate-specific antigen level during active surveillance with targeted and systematic prostate biopsy.
Outcomes of patients treated for monomorphic B-cell post-transplant lymphoproliferative disorder: A single-center experience.
Palbociclib plus endocrine therapy or GnRH analogs versus capecitabine or placebo for HR+/HER2- metastatic breast cancer: A systematic review and meta-analysis.
Patient-reported health experiences among US immigrant patients with cancer.
Patterns of failure and treatment for hepatocellular carcinoma after immune checkpoint inhibitors.
Peripheral myeloid-derived suppressor cell as a biomarker for diagnosing and predicting the treatment efficacy of colorectal cancer.
Phase 2, multicenter study of frontline maintenance therapy with lifileucel plus pembrolizumab in advanced non-small cell lung cancer.
Prognostic and predictive role of HLA supertypes in pMMR mCRC patients receiving FOLFOXIRI/bev ± atezolizumab in the AtezoTRIBE study.
Prognostic utility of ctDNA before and after trimodality therapy (TMT) for muscle invasive bladder cancer.
PSMA-based PET imaging in newly diagnosed, high-risk localized prostate cancer, a National Cancer Institute (NCI) Cancer Moonshot trial.
Real-world predictors of adverse clinical outcomes in pancreatic cancer using a machine-learning framework.
Real-world treatment patterns and time-to-treatment discontinuation among advanced ALK-positive non-small cell lung cancer patients.
Recruitment strategies and enrollment for a virtually supervised exercise intervention for Hispanic/Latinx breast cancer survivors.
Remote physiologic and behavioral monitoring to predict early treatment response in metastatic cancer: High-Definition Oncology study (HDOs) preliminary results.
Reproducibility of the correlation between race and outcomes associated with treatment of HER2+ breast cancer across databases.
Retlirafusp alfa-a bifunctional anti-PD-L1/TGF-βRII agent plus nab-paclitaxel and carboplatin in pre-treated recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): A prospective, sing
R-Spondin 3 as an independent biomarker and potential therapeutic target for colon cancer immunotherapy.
Serious infections in patients with CLL/SLL treated with combination venetoclax and obinutuzumab compared with those treated with zanubrutinib: A real-world study.
Survival after osimertinib dose-reduction, discontinuation in 1L EGFR -mutated metastatic non-small cell lung cancer (mNSCLC).
Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): Results from a randomized, double-blin
Telehealth and cancer care delivery: An updated real-world analysis of the impact of telehealth on patient access and treatment utilization at a comprehensive cancer center.
The germline and somatic landscape of uterine leiomyosarcoma.
The immunogenomic landscape of primary and metastatic gastroesophageal adenocarcinoma.
The role of salvage cystectomy after prior trimodality therapy.
Tumor-wide RNA splicing aberrations and their potential as therapeutic neoantigen targets.
Two cycles of neoadjuvant therapy with low-dose radiotherapy, PD-1 inhibitor tislelizumab, albumin-bound paclitaxel, and cisplatin for resectable locally advanced head and neck squamous cell carcinoma
Utilization and timeliness of next-generation sequencing testing for patients with resected or metastatic non-small cell lung cancer: A real-world analysis.
Zanidatamab dose optimization in patients with HER2-positive biliary tract cancer (BTC).

« prev Page 2/2